{"hands_on_practices": [{"introduction": "Understanding inducible systems begins with the principle of specificity. Much like a key only fits a specific lock, an inducer molecule is designed to interact with a particular regulatory protein. This first practice problem [@problem_id:2043711] presents a classic scenario that tests this core concept, challenging you to diagnose an experimental failure by considering the specific molecular pairing of the chosen promoter system and the inducer.", "problem": "A synthetic biology student is working with a strain of *E. coli* that has been transformed with a plasmid. This plasmid carries a gene encoding a Green Fluorescent Protein (GFP), which is placed under the transcriptional control of the arabinose-inducible promoter, $P_{BAD}$. The expression from the $P_{BAD}$ promoter is regulated by the AraC protein, which is also encoded on the same plasmid.\n\nTo induce the expression of GFP, the student adds Isopropyl β-d-1-thiogalactopyranoside (IPTG), a common laboratory inducing agent, to the bacterial culture medium. After several hours of incubation, the student measures the fluorescence of the culture and finds it to be indistinguishable from a negative control (i.e., no GFP expression is observed).\n\nAssuming the plasmid sequence is correct and the *E. coli* strain is healthy and capable of protein expression, which of the following statements provides the most accurate and fundamental explanation for this experimental failure?\n\nA. IPTG is a toxic substance at the concentrations used for induction, which leads to cell death and prevents any protein synthesis.\n\nB. The $P_{BAD}$ promoter is activated by the AraC protein only when AraC is bound to arabinose. IPTG is an inducer for a different system, the lac operon, and does not bind to or allosterically regulate the AraC protein.\n\nC. The $P_{BAD}$ promoter is known for its high basal (\"leaky\") expression, and the addition of a non-cognate inducer like IPTG triggers a strong, global stress response in the cell that actively represses all transcription from the plasmid.\n\nD. The chromophore of the Green Fluorescent Protein requires arabinose as a chemical co-factor for its correct folding and maturation. Therefore, even if transcription occurred, the resulting protein would not be fluorescent.\n\nE. IPTG is a competitive inhibitor of the AraC protein. It binds to the same active site as arabinose but fails to induce the conformational change required for transcriptional activation, thus keeping the promoter in a permanently \"off\" state.", "solution": "We identify the regulatory architecture: the GFP gene is under the $P_{BAD}$ promoter, which is transcriptionally controlled by the AraC protein. The canonical mechanism is that AraC, in the absence of arabinose, adopts a conformation that favors DNA looping and repression of $P_{BAD}$. When arabinose binds AraC, AraC undergoes an allosteric conformational change that disrupts looping and promotes binding of AraC to activating sites (*I1* and *I2*), recruiting RNA polymerase to initiate transcription from $P_{BAD}$. Therefore, induction of $P_{BAD}$ fundamentally requires the cognate inducer arabinose acting through AraC.\n\nThe experimental manipulation adds IPTG, which is a gratuitous inducer of the lac operon. Mechanistically, IPTG binds to the LacI repressor, reducing LacI’s affinity for the lac operator and thereby de-repressing lac-derived promoters (e.g., $P_{lac}$ or $P_{tac}$/$P_{trc}$). IPTG is an analog of allolactose and is not a ligand for AraC; there is no allosteric regulation of AraC by IPTG. Consequently, in a system where expression relies on AraC activation of $P_{BAD}$, adding IPTG will not convert AraC to its activating conformation, so transcription from $P_{BAD}$ remains off and GFP is not expressed.\n\nWe evaluate each option against this regulatory logic:\n\n- Option A posits IPTG toxicity at induction concentrations. This is not the fundamental explanation: IPTG is widely used at standard concentrations that are non-toxic to healthy E. coli, and the problem states the strain is healthy and capable of expression. Thus A is not the most accurate fundamental cause.\n\n- Option B states that $P_{BAD}$ activation requires AraC bound to arabinose, and IPTG is a lac operon inducer that does not regulate AraC. This matches the known, specific ligand–regulator relationships and explains why no GFP is observed when IPTG is used: the correct inducer (arabinose) was not provided.\n\n- Option C claims high basal leakiness of $P_{BAD}$ and a global stress response caused by a non-cognate inducer. $P_{BAD}$ is generally considered relatively tight (low basal expression) under standard conditions, and there is no established mechanism by which IPTG broadly represses transcription from $P_{BAD}$. This is not an accurate or fundamental explanation.\n\n- Option D claims GFP requires arabinose for chromophore maturation. GFP chromophore formation is autocatalytic and requires oxygen, not arabinose; arabinose is not a co-factor for GFP folding or maturation. Thus D is incorrect.\n\n- Option E asserts IPTG is a competitive inhibitor of AraC at the arabinose site. There is no evidence that IPTG binds AraC; IPTG is specific for LacI and does not occupy AraC’s arabinose-binding pocket. Therefore E is incorrect.\n\nBy process of elimination and mechanistic correctness, the most accurate and fundamental explanation is that IPTG does not induce the $P_{BAD}$/AraC system, so no GFP expression occurs. This corresponds to option B.", "answer": "$$\\boxed{B}$$", "id": "2043711"}, {"introduction": "Once a promoter is activated, how quickly does the protein product accumulate? The answer lies in the dynamic interplay of protein production, degradation, and dilution from cell division. In this problem [@problem_id:2043722], you will use a simple mathematical model to capture these processes and derive an expression for the system's response time, a crucial parameter for designing time-sensitive genetic circuits.", "problem": "A synthetic biologist is engineering an *E. coli* strain to produce a therapeutic protein. The gene for this protein is placed under the control of an inducible promoter system. The bacterial culture is grown in a chemostat, which maintains a constant population density and a constant specific growth rate, denoted by $\\mu$. At time $t=0$, a chemical inducer is added to the culture, triggering the expression of the therapeutic protein.\n\nAssume the following model for the intracellular concentration of the protein, $P(t)$:\n1.  Once induced, the protein is produced at a constant, zero-order rate $k_p$.\n2.  The protein is actively degraded by cellular proteases via a first-order process with a rate constant $\\gamma$.\n3.  As the cells divide, the protein is partitioned between daughter cells, leading to an effective dilution of the protein concentration within any single cell. This dilution process is also modeled as a first-order decay with a rate constant equal to the specific growth rate $\\mu$.\n4.  The initial concentration of the therapeutic protein at $t=0$ is zero, i.e., $P(0)=0$.\n\nDerive an analytical expression for the time $t_{1/2}$ it takes for the protein concentration to reach exactly half of its maximum possible steady-state value. Express your answer in terms of the given parameters $k_p$, $\\gamma$, and $\\mu$, as needed.", "solution": "Let $P(t)$ denote the intracellular protein concentration. The processes of production, active degradation, and dilution by growth yield the linear ordinary differential equation\n$$\n\\frac{dP}{dt}=k_{p}-(\\gamma+\\mu)P,\n$$\nwith initial condition $P(0)=0$. This is a first-order linear ODE. Using the integrating factor $\\exp\\left((\\gamma+\\mu)t\\right)$, we obtain\n$$\n\\frac{d}{dt}\\left(P(t)\\exp\\left((\\gamma+\\mu)t\\right)\\right)=k_{p}\\exp\\left((\\gamma+\\mu)t\\right).\n$$\nIntegrating from $0$ to $t$ and using $P(0)=0$ gives\n$$\nP(t)\\exp\\left((\\gamma+\\mu)t\\right)=\\int_{0}^{t}k_{p}\\exp\\left((\\gamma+\\mu)\\tau\\right)\\,d\\tau=\\frac{k_{p}}{\\gamma+\\mu}\\left(\\exp\\left((\\gamma+\\mu)t\\right)-1\\right).\n$$\nSolving for $P(t)$,\n$$\nP(t)=\\frac{k_{p}}{\\gamma+\\mu}\\left(1-\\exp\\left(-(\\gamma+\\mu)t\\right)\\right).\n$$\nThe steady-state concentration is\n$$\nP_{\\text{ss}}=\\lim_{t\\to\\infty}P(t)=\\frac{k_{p}}{\\gamma+\\mu}.\n$$\nDefine $t_{1/2}$ by $P(t_{1/2})=\\frac{1}{2}P_{\\text{ss}}$. Substituting the expression for $P(t)$ and canceling the common factor $\\frac{k_{p}}{\\gamma+\\mu}$ yields\n$$\n1-\\exp\\left(-(\\gamma+\\mu)t_{1/2}\\right)=\\frac{1}{2}.\n$$\nEquivalently,\n$$\n\\exp\\left(-(\\gamma+\\mu)t_{1/2}\\right)=\\frac{1}{2}.\n$$\nTaking the natural logarithm,\n$$\n-(\\gamma+\\mu)t_{1/2}=\\ln\\left(\\frac{1}{2}\\right)=-\\ln 2,\n$$\nwhich gives\n$$\nt_{1/2}=\\frac{\\ln 2}{\\gamma+\\mu}.\n$$\nThis result holds for $\\gamma+\\mu>0$, which is guaranteed by positive degradation and growth rates.", "answer": "$$\\boxed{\\frac{\\ln 2}{\\gamma+\\mu}}$$", "id": "2043722"}, {"introduction": "A key goal in synthetic biology is not just to use genetic parts, but to engineer them for specific functions. This often involves tuning the sensitivity and output levels of an inducible system. This practice [@problem_id:2043765] explores how to rationally modify a system's dose-response curve by altering the binding affinity between a repressor and its DNA operator site, providing insight into engineering predictable genetic responses.", "problem": "A synthetic biologist designs a simple genetic circuit in *E. coli*. The circuit consists of a strong promoter followed by an operator site, which controls the expression of a gene for a Green Fluorescent Protein (GFP). The expression of GFP is repressed by a repressor protein, which binds to the operator site and blocks transcription. This repression can be relieved by adding an inducer molecule to the growth medium. The inducer binds to the repressor protein, causing a conformational change that prevents the repressor from binding to the operator DNA.\n\nThe behavior of this \"wild-type\" (WT) circuit is characterized by a dose-response curve, which plots the steady-state GFP concentration as a function of the inducer concentration. We define three key properties of this curve:\n1.  **Basal Expression**: The low-level GFP expression observed in the complete absence of the inducer.\n2.  **Maximum Expression**: The saturated GFP expression level achieved at very high concentrations of the inducer.\n3.  **Sensitivity**: Characterized by the concentration of inducer, $K_{\\text{inducer}}$, required to achieve half of the maximum possible *increase* in expression above the basal level. A lower $K_{\\text{inducer}}$ indicates higher sensitivity to the inducer.\n\nNow, a mutation is introduced into the operator DNA sequence. This mutation weakens the binding affinity between the repressor protein and the operator site, but it does not affect any other part of the circuit (e.g., promoter strength, repressor protein concentration, or the interaction between the repressor and the inducer).\n\nCompared to the wild-type (WT) circuit, how will the three properties of the dose-response curve for this mutated (MUT) circuit change?\n\nA. Basal expression increases, Maximum expression remains unchanged, $K_{\\text{inducer}}$ decreases.\n\nB. Basal expression decreases, Maximum expression remains unchanged, $K_{\\text{inducer}}$ increases.\n\nC. Basal expression increases, Maximum expression decreases, $K_{\\text{inducer}}$ decreases.\n\nD. Basal expression remains unchanged, Maximum expression remains unchanged, $K_{\\text{inducer}}$ decreases.\n\nE. Basal expression increases, Maximum expression increases, $K_{\\text{inducer}}$ increases.", "solution": "We model simple repression with an operator-bound repressor that blocks transcription. Let $I$ be the inducer concentration, $E(I)$ the steady-state GFP expression, $E_{\\max}$ the unrepressed expression level, and $f_{A}(I)$ the fraction of repressor molecules in the DNA-binding active state at inducer concentration $I$. The operator occupancy by active repressor scales with $f_{A}(I)$ and with an effective repression strength parameter $\\lambda$ that is proportional to the ratio of active repressor availability to the operator dissociation constant $K_{R}$. A standard thermodynamic occupancy model gives\n$$\nE(I)=\\frac{E_{\\max}}{1+\\lambda f_{A}(I)}.\n$$\nHere $\\lambda$ encapsulates the operator-binding affinity: weakening operator binding increases $K_{R}$ and thus decreases $\\lambda$. The inducer inactivates the repressor so that $f_{A}(I)$ is a monotonically decreasing function of $I$ with $f_{A}(0)=1$ and $\\lim_{I\\to\\infty}f_{A}(I)=0$. The mutation changes only $K_{R}$ (hence $\\lambda$), not $E_{\\max}$, not the total repressor level, and not $f_{A}(I)$.\n\nBasal expression (no inducer) is obtained by setting $I=0$ so $f_{A}(0)=1$:\n$$\nE_{\\text{basal}}=\\frac{E_{\\max}}{1+\\lambda}.\n$$\nIf the operator-binding is weakened, $K_{R}$ increases and thus $\\lambda$ decreases; because $E_{\\text{basal}}$ is an increasing function of decreasing $\\lambda$, the basal expression increases.\n\nMaximum expression corresponds to saturating inducer, $I\\to\\infty$, so $f_{A}(I)\\to 0$:\n$$\n\\lim_{I\\to\\infty}E(I)=\\frac{E_{\\max}}{1+0}=E_{\\max}.\n$$\nThis is independent of $\\lambda$, so the maximum expression remains unchanged by the operator mutation.\n\nSensitivity $K_{\\text{inducer}}$ is defined as the inducer concentration that yields half of the maximum possible increase above basal. Denote $I_{50}$ as the $I$ satisfying\n$$\nE(I_{50})-E_{\\text{basal}}=\\frac{1}{2}\\left(E_{\\max}-E_{\\text{basal}}\\right).\n$$\nUsing $E(I)=E_{\\max}/(1+\\lambda f_{A}(I))$ and $E_{\\text{basal}}=E_{\\max}/(1+\\lambda)$, the right-hand side equals\n$$\n\\frac{1}{2}\\left(E_{\\max}-\\frac{E_{\\max}}{1+\\lambda}\\right)=\\frac{E_{\\max}}{2}\\cdot\\frac{\\lambda}{1+\\lambda}.\n$$\nTherefore\n$$\n\\frac{E_{\\max}}{1+\\lambda f_{A}(I_{50})}-\\frac{E_{\\max}}{1+\\lambda}=\\frac{E_{\\max}}{2}\\cdot\\frac{\\lambda}{1+\\lambda}.\n$$\nDivide both sides by $E_{\\max}$ and rearrange to solve for $f_{A}(I_{50})$:\n$$\n\\frac{1}{1+\\lambda f_{A}(I_{50})}=\\frac{1+\\lambda/2}{1+\\lambda}\n\\quad\\Longrightarrow\\quad\n1+\\lambda f_{A}(I_{50})=\\frac{1+\\lambda}{1+\\lambda/2},\n$$\n$$\n\\lambda f_{A}(I_{50})=\\frac{\\lambda/2}{1+\\lambda/2}\n\\quad\\Longrightarrow\\quad\nf_{A}(I_{50})=\\frac{1}{2+\\lambda}.\n$$\nThus the target active fraction at half-maximal increase is $f_{A}^{*}(\\lambda)=\\frac{1}{2+\\lambda}$. Weakening operator binding decreases $\\lambda$, which increases $f_{A}^{*}$ because $f_{A}^{*}$ is a strictly decreasing function of $\\lambda$. Since $f_{A}(I)$ decreases monotonically with $I$, achieving a larger target value $f_{A}^{*}$ requires a smaller inducer concentration. Therefore $I_{50}$, and hence $K_{\\text{inducer}}$, decreases.\n\nCollecting the three effects relative to the wild type: basal expression increases, maximum expression remains unchanged, and $K_{\\text{inducer}}$ decreases. This corresponds to option A.", "answer": "$$\\boxed{A}$$", "id": "2043765"}]}